Sanjay Gupta: Can Science and God Coexist?
Faith and science may often seem at odds with one another, but renowned geneticist and former NIH director, Dr. Francis Collins, says that he sees…
Thought Leader: Sanjay Gupta
By Scott Gottlieb (original source The Wall Street Journal)
“The first nation to develop a vaccine for Covid-19 could have an economic advantage as well as a tremendous public-health achievement. Doses will be limited initially as suppliers ramp up, and a country will focus on inoculating most of its own population first. Even with extraordinary international collaboration among multiple companies, it could be years before a vaccine is produced at a scale sufficient to help the entire world. The first country to the finish line will be first to restore its economy and global influence. America risks being second.
China is making rapid progress, with three vaccines entering advanced development. Chinese officials say they could have a vaccine available for widespread use next year. The Europeans are also making progress. While friendly nations will try to share a successful product—to a point—the U.S. can’t rely on vaccines from China or even Europe being available in America quickly. So it’s important to take steps to speed up progress in the U.S., and to prepare to manufacture such a vaccine on a global scale. A more prepared U.S. could inoculate Americans quickly and share the product with others, particularly low-income nations that can’t develop their own vaccines and need protection.
More than 70 companies and research teams are working on a vaccine, but fewer than 20 have the experience and manufacturing scale to pull a product through development. Only five or six operate primarily in the U.S., which means foreign governments might try to make a claim on a vaccine before America can. Each company is taking a slightly different approach, spreading bets and increasing the chance for success. (I serve on the board of one of them, Pfizer Inc. )
To win the race to a vaccine, America needs to engineer a development and regulatory process that is unprecedented in scope and urgency. Testing six or more candidate vaccines at once during a pandemic has never been tried anywhere. But it can be done.”
Sanjay Gupta: Can Science and God Coexist?
Faith and science may often seem at odds with one another, but renowned geneticist and former NIH director, Dr. Francis Collins, says that he sees…
Thought Leader: Sanjay Gupta
Marc Short on what to expect from DOGE in relation to next year’s legislative agenda
Marc Short comments on what to expect from DOGE in relation to next year’s legislative agenda for CNBC. Looking for a great keynote or public…
Thought Leader: Marc Short
Marc Short on whether Musk has permanently changed how congressional communication functions
In this video, Marc Short joins CNBC to discuss whether Musk and Twitter have permanently changed how congressional communication functions and what to expect for…
Thought Leader: Marc Short